Lead Product(s): Tideglusib
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2020
Trial to assess AMO-02 in treatment of congenital myotonic dystrophy to begin patient enrollment in early 2020.